Kyverna Moves Closer to First Autoimmune CAR-T Approval
Autolus Reports Encouraging CAR-T Data in Severe Lupus
FDA Signals Support for Autoimmune CAR-T Development
In Vivo CAR-T Shows Promise as Next-Generation Cell Therapy
CASTLE Trial Highlights Broad Potential Across Autoimmune Diseases
Novartis & Bristol Myers Squibb Pause Autoimmune CAR-T Trials Following Safety Reviews
December 1-3, 2026 | Philadelphia, PA